Dividend Champion, Contender, And Challenger Highlights: Week October 25Seeking Alpha · 19 hr ago
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research · 23 hr ago
What's Going On with Bristol Myers Squibb Stock on Friday?Benzinga · 1 day ago
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?Zacks Investment Research · 1 day ago
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSGuruFocus · 1 day ago
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026Business Wire · 1 day agoBristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $1.60 | $2.04 | Beat |
| Apr 30, 2026 | $1.42 | $1.58 | Beat |
| Feb 5, 2026 | $1.23 | $1.26 | Beat |
| Oct 30, 2025 | $1.52 | $1.63 | Beat |
| Jul 31, 2025 | $1.09 | $1.46 | Beat |
| Apr 24, 2025 | $1.49 | $1.80 | Beat |